Average Co-Inventor Count = 7.23
ph-index = 12
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Bristol-myers Squibb Compnay (55 from 3,681 patents)
2. Universitéde Montreal (6 from 183 patents)
3. Other (5 from 832,680 patents)
4. Britsol-myers Squibb Company (1 from 3 patents)
5. University of Pennsylvania (2,595 patents)
61 patents:
1. 12168655 - Apelin receptor agonists and methods of use
2. 12097241 - Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides
3. 12097242 - Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides
4. 12084452 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation
5. 11498903 - 2-(1,1'-biphenyl)-1H-benzodimidazole derivatives and related compounds as apelin and APJ agonists for treating cardiovascular diseases
6. 11390616 - Apelin receptor agonists and methods of use
7. 11364281 - Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof
8. 11185570 - Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides
9. 10966967 - Aryl dihydropyridinones and piperidinone MGAT2 inhibitors
10. 10822343 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation
11. 10695328 - Aryl dihydropyridinones and piperidinone MGAT2 inhibitors
12. 10669261 - Heteroarylhydroxypyrimidinones as agonists of the APJ receptor
13. 10590113 - 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists
14. 10428077 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation
15. 10392347 - 2,4-dihydroxy-nicotinamides as APJ agonists